B12-functionalized PEGylated liposomes for the oral delivery of insulin: In vitro and in vivo studies

Sarhadi, Susan; Moosavian, Seyedeh Alia; Mashreghi, Mohammad; Rahiman, Niloufar; Golmohamadzadeh, Shiva; Tafaghodi, Mohsen; Sadri, Kayvan; Chamani, Jamshidkhan; Jaafari, Mahmoud Reza

doi:10.1016/j.jddst.2022.103141

Cited by 15 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liposomes are the oldest and most widely studied lipid-based delivery system because of their biocompatibility. The main components in a liposome are the phospholipids organized in a bilayer structure which form vesicles in the presence of water. , Various types of liposome-based drugs are currently either approved or in various phases of drug development . Liposomal drug carriers interact extensively with the immune system, and one study has shown that liposomal anticancer drug carriers can reduce the number of tumor-antigen-specific cytotoxic T-cells and promote tumor growth in mice .…”

Section: Lipid-based Ndds In Cancer Therapymentioning

confidence: 99%

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Khan

Hossain

et al. 2022

ACS Appl. Bio Mater.

160

View full text Add to dashboard Cite

Traditional treatment approaches for cancer involve intravenous chemotherapy or other forms of drug delivery. These therapeutic measures suffer from several limitations such as nonspecific targeting, poor biodistribution, and buildup of drug resistances. However, significant technological advancements have been made in terms of superior modes of drug delivery over the last few decades. Technical capability in analyzing the molecular mechanisms of tumor biology, nanotechnologyparticularly the development of biocompatible nanoparticles, surface modification techniques, microelectronics, and material scienceshas increased. As a result, a significant number of nanostructured carriers that can deliver drugs to specific cancerous sites with high efficiency have been developed. This particular maneuver that enables the introduction of a therapeutic nanostructured substance in the body by controlling the rate, time, and place is defined as the nanostructured drug delivery system (NDDS). Because of their versatility and ability to incorporate features such as specific targeting, water solubility, stability, biocompatibility, degradability, and ability to reverse drug resistance, they have attracted the interest of the scientific community, in general, and nanotechnologists as well as biomedical scientists. To keep pace with the rapid advancement of nanotechnology, specific technical aspects of the recent NDDSs and their prospects need to be reported coherently. To address these ongoing issues, this review article provides an overview of different NDDSs such as lipids, polymers, and inorganic nanoparticles. In addition, this review also reports the challenges of current NDDSs and points out the prospective research directions of these nanocarriers. From our focused review, we conclude that still now the most advanced and potent field of application for NDDSs is lipid-based, while other significantly potential fields include polymer-based and inorganic NDDSs. However, despite the promises, challenges remain in practical implementations of such NDDSs in terms of dosage and stability, and caution should be exercised regarding biocompatibility of materials. Considering these aspects objectively, this review on NDDSs will be particularly of interest for small-to-large scale industrial researchers and academicians with expertise in drug delivery, cancer research, and nanotechnology.

show abstract

Section: Lipid-based Ndds In Cancer Therapymentioning

confidence: 99%

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Khan

Hossain

et al. 2022

ACS Appl. Bio Mater.

160

View full text Add to dashboard Cite

show abstract

“…The presence of adult worms within lymphatic vessels resulted in increased vessel dilatation. Therefore, the LDD of therapeutic molecules is essential to ensure the complete eradication of adult worms within lymph nodes (Sarhadi et al 2022 ). Additionally, a high level of HIV is detected in mononuclear cells within the lymph node (Woldemeskel et al 2022 ).…”

Section: Biomedical Applications Of Lddmentioning

confidence: 99%

Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons

2023

View full text Add to dashboard Cite

Lymphatic drug targeting is an effective approach for targeting immunomodulators, and chemotherapeutic drugs at a specific organ or cellular location. The cellular, paracellular, and dendritic cell trafficking machinery are involved in the lymphatic transport of therapeutic agents. The engineering of triggered and hybrid lymphatic drug delivery systems (LDDS) is a promising strategy to fight cancer metastasis and microbial pandemics. Hybrid lymphatic drug delivery systems can be tailored and developed by grafting the conventional LDDS with biological agents. Thus, hybrid LDDS could collect the benefits of conventional and biological delivery systems. Moreover, the fabrication of triggered LDDS increases drug accumulation in the lymphatic system in the response to an internal stimulus such as pH, and redox status or external such as magnetic field, temperature, and light. Stimuli-responsive LDD systems prevent premature release of payload and mediate selective drug biodistribution. This improves therapeutic impact and reduces the systemic side effect of anticancer, immunomodulatory, and antimicrobial therapeutics. This review highlights the challenges and future horizons of nanoscaled-triggered LDDS and their influence on the lymphatic trafficking of therapeutic molecules. Graphical abstract

show abstract

“…Other studies have taken advantage of the fact that tumor cells can overexpress the folate receptor, while normal cells lack it; thus, folate conjugated liposomes are targeted for the treatment of cancers such as colon cancer (Handali et al, 2018). Sarhadi et al (2022) modified pegylated liposomes with B12 and used B12 to target the intestinal receptors to mediate liposomal endocytosis and to improve the absorption of insulin embedded in liposomes. The results showed that the distribution characteristics of B12-modified pegylated liposome in mouse tissues were significantly better than that of pegylated liposome, and the bioavailability of B12-modified pegylated liposome was 2.3 times than that of pegylated liposome.…”

Section: Vitamins As Decoratormentioning

confidence: 99%

“…Sarhadi et al. (2022) modified pegylated liposomes with B12 and used B12 to target the intestinal receptors to mediate liposomal endocytosis and to improve the absorption of insulin embedded in liposomes. The results showed that the distribution characteristics of B12‐modified pegylated liposome in mouse tissues were significantly better than that of pegylated liposome, and the bioavailability of B12‐modified pegylated liposome was 2.3 times than that of pegylated liposome.…”

Section: Strategies To Improve the Utilization Of Liposomes For Gut T...mentioning

confidence: 99%

Specific surface modification of liposomes for gut targeting of food bioactive agents

Zhang

Pan

et al. 2023

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

Liposomes have become a research hotspot in recent years as food delivery systems with attractive properties, including the bilayer structure assembled like the cell membrane, reducing the side‐effect and improving environmental stability of cargos, controlling release, extending duration of functional ingredients, and high biodegradable and biocompatible abilities in the body. However, the conventional liposomes lack stability during storage and are weak in targeted absorption in the gastrointestinal track. At present, surface modification has been approved to be an effective platform to shield these barricades and help liposomes deliver the agents safely and effectively to the ideal site. In this review, the gastrointestinal stability of conventional liposomes, cargo release models from liposomes, and the biological fate of the core materials after release were emphasized. Then, the strategies in both physical and chemical perspectives to improve the stability and utilization of liposomes in the gastrointestinal tract, and the emerging approaches for improving gut targeting by specifically modified liposomes and the intestinal receptors relative to liposomes/cargos absorption were highlighted. Last but not the least, the safety, challenges, and opportunities for the improvement of liposomal bioavailability were also discussed to inspire new applications of liposomes as oral carriers.

show abstract

B12-functionalized PEGylated liposomes for the oral delivery of insulin: In vitro and in vivo studies

Cited by 15 publications

References 40 publications

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons

Specific surface modification of liposomes for gut targeting of food bioactive agents

Contact Info

Product

Resources

About